https://www.fool.com/investing/2017/04/23/should-gilead-sciences-be-worried-about-allergan.aspx?source=iedfolrf0000001
Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
2
fool:-3402600035961810023
2
http://www.zacks.com/stock/news/256887/allergan-agn-collaborates-with-novartis-to-treat-nash?cid=CS-ZC-FT-256887
Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
0
zc:2062434149420569598
0
http://www.zacks.com/stock/news/256645/did-pharma-biotech-mas-pick-pace-in-q1?cid=CS-ZC-FT-256645
Apr 18, 2017 - Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
0
zc:7405667323365513109
0
http://www.zacks.com/stock/news/256284/aerie-reports-positive-data-on-ophthalmic-drug-rhopressa?cid=CS-ZC-FT-256284
Apr 13, 2017 - Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.
0
zc:2949573037227836839
0
http://www.zacks.com/stock/news/254783/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk?cid=CS-ZC-FT-254783
Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
0
zc:492235546681850990
0
http://www.zacks.com/stock/news/254739/why-equal-weighted-mutual-funds-scoring-over-index-funds?cid=CS-ZC-FT-254739
Mar 30, 2017 - Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
0
zc:1386072103840634420
0
http://www.zacks.com/stock/news/254397/allergan-acne-candidate-meets-endpoints-in-phase-iii-studies?cid=CS-ZC-FT-254397
Mar 28, 2017 - Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
0
zc:2644788473621104596
0
http://www.zacks.com/stock/news/254077/amgens-amgn-humira-biosimilar-receives-approval-in-eu?cid=CS-ZC-FT-254077
Mar 24, 2017 - Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
0
zc:-2437149682913310992
0
http://www.zacks.com/stock/news/254066/teva-pharma-denies-rumors-of-global-workforce-reduction?cid=CS-ZC-FT-254066
Mar 24, 2017 - According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
0
zc:-335056473782618685
0
http://www.zacks.com/stock/news/253879/astrazeneca-stock-rising-in-17-whats-working-in-its-favor?cid=CS-ZC-FT-253879
Mar 23, 2017 - Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
0
zc:-5981921686343196775
0